Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$47.62 USD

47.62
1,462,070

-1.35 (-2.76%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $47.70 +0.08 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?

Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

CORT beats on both earnings and sales in the third quarter of 2024. The company increases the revenue guidance for 2024. Stock falls in after-hours trading.

Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of 51.85% and 6.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Nilanjan Banerjee headshot

Buy Low-Beta Stocks JD, SKWD, CORT, PRA to Beat Election Uncertainty

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. JD, SKWD, CORT & PRA are well-poised to gain.

Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise

Idaho Strategic, Qifu, Sezzle, Corcept and FinWise have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IDR, QFIN, SEZL, CORT, FINW.

Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?

Smart Beta ETF report for JSML

Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?

The mean of analysts' price targets for Corcept (CORT) points to a 43% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Implied Volatility Surging for Corcept Therapeutics (CORT) Stock Options

Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.

Zacks.com featured highlights include Atour Lifestyle, Vertiv, Corcept Therapeutics, Qifu Technology and ADMA Biologics

Atour Lifestyle, Vertiv, Corcept Therapeutics, Qifu Technology and ADMA Biologics are part of the Zacks Screen of the Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength Amid October Volatility

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ATAT, VRT, CORT, QFIN, ADMA.

Zacks.com featured highlights include Corcept Therapeutics, Abercrombie & Fitch and HCI Group

Corcept Therapeutics, Abercrombie & Fitch and HCI Group have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Strong Buy Momentum Stocks as Bull Market Nears 2-Year Mark

Stocks like Corcept Therapeutics, Abercrombie & Fitch and HCI Group have been selected as the momentum picks for the day using the Driehaus strategy.

Here's Why Investors Should Consider Buying Corcept Stock Now

Here, we are discussing some reasons why investing in CORT stock now may turn out to be a prudent move.

Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

Here is how Alnylam Pharmaceuticals (ALNY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.

Here's Why Momentum in Corcept (CORT) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Do Options Traders Know Something About Corcept (CORT) Stock We Don't?

Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.

Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept Shares Rise More Than 45% in Six Months: Here's Why

CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.